Log in

Relevant bibliographies by topics / Antimuscarinics / Journal articles

To see the other types of publications on this topic, follow the link: Antimuscarinics.

Journal articles on the topic 'Antimuscarinics'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antimuscarinics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hopkinson, VCG, and I. Pearce. "Pharmacotherapy in overactive bladder." Journal of Clinical Urology 11, no. 1 (2017): 38–47. http://dx.doi.org/10.1177/2051415817738471.

Full text

Abstract:

Overactive bladder syndrome (OAB) has a high prevalence within the population and has a negative effect on quality of life. Although the precise pathophysiology has yet to be fully elucidated, pharmacotherapeutic agents have been developed targeting two main pathways, antimuscarinic drugs and β3-adrenoreceptor agonists. Conservative management strategies, for example, bladder training, should be used as first-line treatment, with pharmacotherapy used as an adjunct if this is insufficiently effective. Antimuscarinics have a moderate effect on treating the symptoms of OAB, are associated with si

APA, Harvard, Vancouver, ISO, and other styles

2

Athanasopoulos, Anastasios, and Konstantinos Giannitsas. "An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder." Advances in Urology 2011 (2011): 1–8. http://dx.doi.org/10.1155/2011/820816.

Full text

Abstract:

Overactive bladder is a common and bothersome condition. Antimuscarinic agents, as a class, are the cornerstone of medical treatment of overactive bladder. They offer significant improvements in symptoms and patients’ quality of life. Antimuscarinics are generally well tolerated with mild and predictable side effects. Available antimuscarinics have small, yet statistically significant, differences in their efficacy and tolerability profiles. In clinical practice, finding the agent that offers the optimum balance of efficacy and side effects for an individual patient remains the major challenge

APA, Harvard, Vancouver, ISO, and other styles

3

Pranoto, Inez, Tiara Schwarze-Taufiq, Katherine Hui, et al. "DISTINCTIVE NEURONAL RESPONSES TO VARIOUS ANTICHOLINERGICS IN THE ACT COHORT HIPSC-DERIVED NEURONS." Innovation in Aging 8, Supplement_1 (2024): 877–78. https://doi.org/10.1093/geroni/igae098.2838.

Full text

Abstract:

Abstract Anticholinergic medications remain widely used among older adults despite evidence of safety concerns, including dementia risk. Clinical cohort studies have linked certain anticholinergic classes, such as antidepressants and bladder antimuscarinics, to higher dementia risk. However, distinguishing whether this association stems from individuals’ predisposed conditions or drug-induced neuronal dysfunctions remains challenging. To address this, we used human induced pluripotent stem cell-derived neurons (hiPSC-Ns) from participants in the Adult Changes in Thought Study (ACT) aging study

APA, Harvard, Vancouver, ISO, and other styles

4

Piecoro, Lance T., Daniel P. Wermeling, Frederick A. Schmitt, and J. Wesson Ashford. "Seizures in Patients Receiving Concomitant Antimuscarinics and Acetylcholinesterase Inhibitor." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, no. 5 (1998): 1129–32. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03944.x.

Full text

Abstract:

Seizures occurred in two patients with probable Alzheimer's disease who were receiving long‐term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. In both patients seizures were associated with discontinuation of short‐term agents with high antimuscarinic properties. Hence, abrupt discontinuation of antimuscarinics or anticholinergics with high antimuscarinic properties in patients receiving long‐term acetylcholinesterase inhibition therapy may be associated with a reduction of seizure threshold. With increasing administration of acetylcholinesterase inhibitors for pa

APA, Harvard, Vancouver, ISO, and other styles

5

Sartori, Luisa Gracio Ferreira, Bruno Monteiro Nunes, Daniela Farah, et al. "Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 45, no. 06 (2023): 337–46. http://dx.doi.org/10.1055/s-0043-1770093.

Full text

Abstract:

Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic

APA, Harvard, Vancouver, ISO, and other styles

6

Liu, Qiang, Deyi Luo, Tongxin Yang, Banghua Liao, Hong Li, and Kun-Jie Wang. "Protective Effects of Antimuscarinics on the Bladder Remodeling After Bladder Outlet Obstruction." Cellular Physiology and Biochemistry 44, no. 3 (2017): 907–19. http://dx.doi.org/10.1159/000485358.

Full text

Abstract:

Background/Aims: Overactive bladder associated with bladder outlet obstruction (BOO) is a highly prevalent condition, which is usually treated with antimuscarinics. However, the potential effects of antimuscarinics on the structure and function of bladder have not been investigated thus far. Methods: Sprague-Dawley(R) rats accepted bladder neck obstruction surgery or sham surgery, and then received treatment of three different antimuscarinics (Solifenacin, Darifenacin, and Tolterodine) or vehicle. After 3, 6 and 12 weeks, the bladder function and structure were measured. The effect of antimusc

APA, Harvard, Vancouver, ISO, and other styles

7

Wagg, Adrian, Demitri Diles, and Todd Berner. "Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data." Journal of Health Economics and Outcomes Research 3, no. 1 (2016): 43–55. http://dx.doi.org/10.36469/9841.

Full text

Abstract:

Background: Overactive bladder (OAB) is a chronic condition which may be associated with a significant negative impact on quality of life. Antimuscarinic drugs are currently the mainstay of medical therapy, but persistence and adherence are generally poor. Treatment switching may be considered in order to maximise benefits from pharmacological therapy, but there are relatively few data on OAB therapy switching to second and third-lines of medication. There are also few formal analyses on the impact of age, gender and choice of initial OAB drug on discontinuation rates. Objectives: To investiga

APA, Harvard, Vancouver, ISO, and other styles

8

Andersson, Karl-Erik. "Drugs and future candidates." Canadian Urological Association Journal 5, no. 5-S2 (2013): 131. http://dx.doi.org/10.5489/cuaj.710.

Full text

Abstract:

Antimuscarinic drugs are still first-line treatment for the symptomsof overactive bladder (OAB) and are associated with good initialresponse rates. Adverse effects and decreasing efficacy overthe longer term do, however, limit their overall effectiveness. Assuch, alternatives to antimuscarinics are needed. The recognitionof the functional contribution of the urothelium, the spontaneousmyocyte activity during bladder filling, and the diversity of nervetransmitters involved in the symptoms of the OAB has sparkedinterest in pharmacologic manipulation of both peripheral andcentral pathophysiology.

APA, Harvard, Vancouver, ISO, and other styles

9

Mandpe, Pankaj, Bala Prabhakar, and Pravin Shende. "Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome." Current Drug Metabolism 21, no. 2 (2020): 79–88. http://dx.doi.org/10.2174/1389200221666200425211139.

Full text

Abstract:

Background: Overactive bladder syndrome is a broadly occurring urological disorder with a distressing impact on the quality of life. The commonly used antimuscarinic drugs show poor patient compliance because of unsatisfactory potency, tolerability and high occurrence of adverse effects such as dry mouth, blurred vision, constipation, dizziness etc. Mirabegron is the first approved β3-adrenoreceptor agonist, used as mono or in combination therapies for overactive bladder syndrome. Objective: The present review provides an insight into the mechanism, pharmacokinetics, toxicokinetics, clinical t

APA, Harvard, Vancouver, ISO, and other styles

10

Trivedi, Sameer, Pranab Patnaik, Yashpal Ramole, Faiz Ahmed Khan, Ragini Srivastava, and Udai Shankar Dwivedi. "Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder." Clinical Medicine Insights: Urology 12 (January 2019): 117956111986490. http://dx.doi.org/10.1177/1179561119864907.

Full text

Abstract:

Background: This study compared urinary and serum nerve growth factor levels and serum C-reactive protein levels in patients with overactive bladder, before and after treatment with antimuscarinic agents, to evaluate their diagnostic and therapeutic importance. Methods: This was a prospective case-control study conducted between February 2014 and December 2014 which included patients with a confirmed diagnosis of overactive bladder (overactive bladder group) and healthy controls (control group). All patients visiting urology out-patient department with urgency, frequency, and urge incontinence

APA, Harvard, Vancouver, ISO, and other styles

11

Yi, Junseok, Seong Jin Jeong, Min Soo Chung, et al. "Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed." Canadian Urological Association Journal 7, no. 1-2 (2013): 88. http://dx.doi.org/10.5489/cuaj.269.

Full text

Abstract:

Objective: Recent studies have investigated a combination of two antimuscarinics for adult neurogenic bladder managed with clean intermittent catheterization or pediatric refractory overactive bladder (OAB). We assessed the efficacy and tolerability of this strategy in adults with idiopathic OAB.Methods: We reviewed 49 patients with idiopathic OAB whoreceived combined antimuscarinic medication. Patients had seriallyreceived different kinds of antimuscarinics as monotherapy, but wished to take combined medication due to a lack of sufficient subjective improvement in urgency, even with dosage es

APA, Harvard, Vancouver, ISO, and other styles

12

Del Popolo, Giulio, Marco Mencarini, and Vincenzo Li Marzi. "Standard Pharmacological Treatment and New Therapies for Overactive Bladder." Urologia Journal 79, no. 1 (2012): 6–13. http://dx.doi.org/10.5301/ru.2012.9032.

Full text

Abstract:

The prevalence of overactive bladder (OAB) in adult males varies from 10.2% to 17.4%, and in females from 7.7 to 31.3. 16.5% of the adult population presents symptoms consistent with OAB; of these, 37.2% are actually affected. The OAB has a significant effect on the quality of life. Initial treatment includes behavioral therapy, physiotherapy and antimuscarinic drugs. In patients where behavioral modifications fail, treatment is associated with antimuscarinics. The antimuscarinic agents used to treat OAB showed some efficacy, but adverse events too, such as dry mouth, constipation, headache an

APA, Harvard, Vancouver, ISO, and other styles

13

Yamamoto, Takanobu, Soichiro Yoshida, Yuya Maezawa, et al. "Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (ADVISR)protocol." BMJ Open 15, no. 3 (2025): e094230. https://doi.org/10.1136/bmjopen-2024-094230.

Full text

Abstract:

IntroductionOveractive bladder (OAB) is a condition characterised by urinary urgency, often accompanied by frequency and nocturia. Antimuscarinics and β3 receptor agonists are first-line therapies that improve urinary symptoms and the quality of life. For insufficient antimuscarinic response, options include dose increase, switching medications or combination therapy. However, evidence for these strategies, especially combinations with vibegron, is limited and needs further study.Methods and analysisThe study is designed as a randomised, open-label, parallel-group, multicentre trial conducted

APA, Harvard, Vancouver, ISO, and other styles

14

Blais, Anne-Sophie, Michelle Bergeron, Geneviève Nadeau, Sophie Ramsay, and Stéphane Bolduc. "Anticholinergic use in children: Persistence and patterns of therapy." Canadian Urological Association Journal 10, no. 3-4 (2016): 137. http://dx.doi.org/10.5489/cuaj.3527.

Full text

Abstract:

<p><strong>Introduction:</strong> Overactive bladder (OAB) symptoms are complex and generally require long-term therapy. Nevertheless, it has been demonstrated that persistence rates of antimuscarinic drug use are low in adults. Better understanding of the treatment patterns of children treated with antimuscarinics could help to improve drug management. Our objective was to evaluate persistence rates of patients under 20 years of age on antimuscarinic therapy over a four-year period.</p><p><strong>Methods:</strong> Patients having received a first-ever

APA, Harvard, Vancouver, ISO, and other styles

15

Ramsay, Sophie, and Stéphane Bolduc. "Overactive bladder in children." Canadian Urological Association Journal 11, no. 1-2S (2017): 74. http://dx.doi.org/10.5489/cuaj.4337.

Full text

Abstract:

Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence, since it negatively affects self-esteem and impairs children’s development. From the patient’s perspective, urgency and urge incontinence can have a significant impact, negatively affecting their quality of life. For a therapy to have true benefit, changes must not only be statistically significant, but must also be perceived as meaningful by the patient. A stepwise approach is favoured to trea

APA, Harvard, Vancouver, ISO, and other styles

16

Wiatr, Tomasz, and Piotr Chłosta. "Safety and efficacy of mirabegron and solifenacin in elderly patient with overactive bladder." Medycyna Faktów 14, no. 1 (2021): 53–57. http://dx.doi.org/10.24292/01.mf.0121.6.

Full text

Abstract:

Lower urinary tract symptoms, including urgency, urgency incontinence, pollakiuria and nocturia are common in the elderly people and has significant impact on quality of life. Pharmacological treatment is recommended when conservative management, such as fluid intake normalization or bladder training, does not alleviate symptoms. Antimuscarinics were often used as the I line treatment for OAB, as these drugs block the activity of the muscarinic M2/M3 receptors in the bladder and provide a significant clinical benefit for OAB symptoms in the elderly people, but their side effects are common, of

APA, Harvard, Vancouver, ISO, and other styles

17

Yeowell, Gillian, Philip Smith, Jameel Nazir, Zalmai Hakimi, Emad Siddiqui, and Francis Fatoye. "Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review." BMJ Open 8, no. 11 (2018): e021889. http://dx.doi.org/10.1136/bmjopen-2018-021889.

Full text

Abstract:

PurposeTo evaluate persistence and adherence of oral pharmacotherapy used in the treatment of overactive bladder (OAB) in a real-world setting.Materials and methodsSystematic literature searches of six electronic publication databases were performed to identify observational studies of patients with OAB treated with antimuscarinics and/or mirabegron. Studies obtaining persistence and adherence data from sources other than electronic prescription claims were excluded. Reference lists of identified studies and relevant systematic reviews were assessed to identify additional relevant studies.Resu

APA, Harvard, Vancouver, ISO, and other styles

18

Fowler, Clare J. "Plant sources of antimuscarinics." BJU International 115 (April 2015): 4–7. http://dx.doi.org/10.1111/bju.13074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Masuda, Hitoshi, Yong-Tae Kim, Shachi Tyagi, Michael B. Chancellor, Fernando de Miguel, and Naoki Yoshimura. "Local Effects of Antimuscarinics." Urologic Clinics of North America 33, no. 4 (2006): 511–18. http://dx.doi.org/10.1016/j.ucl.2006.06.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

De Ridder, Dirk. "Antimuscarinics and Cognitive Function." European Urology 50, no. 2 (2006): 211–12. http://dx.doi.org/10.1016/j.eururo.2006.03.060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Patel, Bhavin, Tamara Bavendam, and Gopal Badlani. "Use of Antimuscarinics in the Elderly." Scientific World JOURNAL 9 (2009): 459–65. http://dx.doi.org/10.1100/tsw.2009.55.

Full text

Abstract:

Overactive bladder (OAB) is a common, costly, and treatable condition in older persons. There is a wide array of available antimuscarinics for the treatment of these conditions; however, their side effect profile and the limited number of studies that evaluate their effect in the elderly curb their use. This review article focuses on OAB and its treatment, with special attention to the use of antimuscarinics in the elderly.

APA, Harvard, Vancouver, ISO, and other styles

22

Gomelsky, Alex, and Roger R. Dmochowski. "OAB Update: Focus on Trospium." Clinical Medicine Insights: Urology 5 (January 2011): CMU.S5068. http://dx.doi.org/10.4137/cmu.s5068.

Full text

Abstract:

Muscarinic receptor antagonists form the mainstay of pharmacologic therapy for overactive bladder (OAB), a prevalent, debilitating, and costly condition. Antimuscarinics differ in their specificity for certain muscarinic receptors, their metabolism, and their ability to cross the blood-brain barrier. Trospium chloride is the only antimuscarinic that is a quarternary amine and its positive charge prevents the crossing of the blood-brain barrier, thus minimizing CNS side effects. Level I evidence supports the efficacy and tolerability of both the immediate-release and extended-release formulatio

APA, Harvard, Vancouver, ISO, and other styles

23

Liao, Chun-Hou, and Hann-Chorng Kuo. "High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment." Medicine 95, no. 45 (2016): e4962. http://dx.doi.org/10.1097/md.0000000000004962.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Andersson, Karl-Erik. "Antimuscarinics for treatment of overactive bladder." Lancet Neurology 3, no. 1 (2004): 46–53. http://dx.doi.org/10.1016/s1474-4422(03)00622-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Wein, Alan J. "Antimuscarinics for Treatment of Overactive Bladder." Journal of Urology 172, no. 3 (2004): 1211. http://dx.doi.org/10.1016/s0022-5347(05)61622-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sidaway, Peter. "β3-adrenoceptor agonists synergize with antimuscarinics". Nature Reviews Urology 13, № 9 (2016): 496. http://dx.doi.org/10.1038/nrurol.2016.137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Wiwanitkit, Viroj. "Scoring for determining effect of antimuscarinics." International Urogynecology Journal 22, no. 3 (2010): 377. http://dx.doi.org/10.1007/s00192-010-1207-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Eberlein, Wolfgang G., Wolfhard W. Engel, Guenter Trummlitz, Guenther Schmidt, and Rudolf Hammer. "Tricyclic compounds as selective antimuscarinics. 2. Structure-activity relationships of M1-selective antimuscarinics related to pirenzepine." Journal of Medicinal Chemistry 31, no. 6 (1988): 1169–74. http://dx.doi.org/10.1021/jm00401a016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hallaz, Mohammad Monsur, BH Nazma Yasmeen, Nadia Sultana, Mahfuza Akter, and Nurul Alam Basher. "Comparison of the efficacy of Solifenacin Succinate and Tolterodine for the treatment of overactive bladder syndrome." Northern International Medical College Journal 8, no. 2 (2017): 231–34. http://dx.doi.org/10.3329/nimcj.v8i2.32557.

Full text

Abstract:

Background : Overactive Bladder Syndrome(OAB) is not an uncommon problem. Although exact incidence of this disease in our country is not known but a significant number of people suffering from this disease seek treatment at the Urology department of different hospitals. At present two common antimuscarinic drug Solifenacin Succinate and Tolterodine are available in our country for the treatment of OAB.Objective : To compare the efficacy of Solifenacin Succinate and Tolterodine to treat OAB.Methodology : This hospital based randomized control trial was conducted in the Department of Urology, Dh

APA, Harvard, Vancouver, ISO, and other styles

30

KIM, Yong-Tae, Michale B. CHANCELLOR, Pradeep TYAGI, et al. "Localized Effects of Antimuscarinics in the Bladder." LUTS: Lower Urinary Tract Symptoms 1 (September 2009): S56—S58. http://dx.doi.org/10.1111/j.1757-5672.2009.00030.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Wyndaele, Jean-Jacques. "Combining antimuscarinics shows promise for overactive bladder." Nature Reviews Urology 7, no. 2 (2010): 66–68. http://dx.doi.org/10.1038/nrurol.2010.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Chaplin, Steve, and Frank Lee. "Antimuscarinics: properties and use in overactive bladder." Prescriber 23, no. 5 (2012): 45–48. http://dx.doi.org/10.1002/psb.877.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Pichurko, B. M., and R. H. Ingram. "Effects of airway tone and volume history on maximal expiratory flow in asthma." Journal of Applied Physiology 62, no. 3 (1987): 1133–40. http://dx.doi.org/10.1152/jappl.1987.62.3.1133.

Full text

Abstract:

We assessed the difference between isovolumic maximal expiratory flows (Vmax) using maneuvers begun at mid-lung volumes, so-called partial expiratory flow-volume curves (P), vs. those begun at full inflation, so-called maximal expiratory flow-volume curves (M), in 10 asthmatic subjects before and following obstruction induced by isocapnic hyperpnea with cold air and before and after bronchodilation with a beta-agonist or antimuscarinic agent. Volume history effects were quantitated as an M-to-P ratio of Vmax at 30% vital capacity (M/P V30). Although M/P V30 was variable among patients at base

APA, Harvard, Vancouver, ISO, and other styles

34

Andersson, Karl-Erik. "Future therapies: Early trials and basic science." Canadian Urological Association Journal 7, no. 9-10 (2013): 179. http://dx.doi.org/10.5489/cuaj.1617.

Full text

Abstract:

Pharmacotherapeutic options for overactive bladder (OAB) include antimuscarinics and the beta3-adrenoceptor (AR) agonist mirabegron. Research and development of novel therapeutic options for OAB continues to be an active field. This review summarizes recent research with the existing therapies as well as the most promising agents in development.

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Antimuscarinics - a possible new class of anti-ischaemics." Inpharma Weekly &NA;, no. 844 (1992): 20. http://dx.doi.org/10.2165/00128413-199208440-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Nardulli, R., E. Losavio, M. Ranieri, et al. "Combined Antimuscarinics for Treatment of Neurogenic Overactive Bladder." International Journal of Immunopathology and Pharmacology 25, no. 1_suppl (2012): 35–41. http://dx.doi.org/10.1177/03946320120250s106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Gordon, R. K., E. Breuer, F. N. Padilla, R. M. Smejkal, and P. K. Chiang. "Distance geometry of alpha-substituted 2,2-diphenylpropionate antimuscarinics." Molecular Pharmacology 36, no. 5 (1989): 766–72. https://doi.org/10.1016/s0026-895x(25)09671-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Moga, Daniela Claudia, Erin L. Abner, Qishan Wu, and Gregory A. Jicha. "Bladder antimuscarinics and cognitive decline in elderly patients." Alzheimer's & Dementia: Translational Research & Clinical Interventions 3, no. 1 (2017): 139–48. http://dx.doi.org/10.1016/j.trci.2017.01.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Bostock, Clare, and Christopher McDonald. "Antimuscarinics in older people: dry mouth and beyond." Dental Update 43, no. 2 (2016): 186–91. http://dx.doi.org/10.12968/denu.2016.43.2.186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Stewart, Ellie. "Prescribing antimuscarinics for women with an overactive bladder." Nurse Prescribing 9, no. 2 (2011): 82–87. http://dx.doi.org/10.12968/npre.2011.9.2.82.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Wyndaele, J. J. "Antimuscarinics for the treatment of neurogenic detrusor overactivity." Spinal Cord 51, no. 6 (2013): 431. http://dx.doi.org/10.1038/sc.2013.55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Fortin, Alexandra, Valérie Morin, Sophie Ramsay, Pascale Gervais, and Stéphane Bolduc. "Adherence to antimuscarinics in children with overactive bladder." Paediatrics & Child Health 22, no. 5 (2017): 255–58. http://dx.doi.org/10.1093/pch/pxx055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Panayi, Demetri C., Paris Tekkis, Ruwan Fernando, and Vikram Khullar. "Measuring the effect of antimuscarinics in the bladder." International Urogynecology Journal 22, no. 3 (2011): 379. http://dx.doi.org/10.1007/s00192-010-1313-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Huang, E. Y. H., H. J. Chung, C. C. Lin, et al. "Post-operative continuous use of antimuscarinics in BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study." European Urology Supplements 16, no. 3 (2017): e931-e932. http://dx.doi.org/10.1016/s1569-9056(17)30596-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Bland, Tyler, and Ethan Overfelt. "Abstract 1744: Chemoresistant non-small cell lung cancer: A resensitizing strategy utilizing antimuscarinics." Cancer Research 83, no. 7_Supplement (2023): 1744. http://dx.doi.org/10.1158/1538-7445.am2023-1744.

Full text

Abstract:

Abstract Background: Advanced non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths in the United States and worldwide. This is largely due to intrinsic or acquired therapy resistance. The current study investigates the potential of a repurposed antimuscarinic overactive bladder drug to resensitize chemotherapy-resistant NSCLC to chemotherapy-induced apoptosis. Methods: The chemotherapy drug, docetaxel (DTX), resistant human NSCLC cell cultures (A549R) were established to recapitulate the clinical emergence of chemoresistance. These cultures were used to harvest t

APA, Harvard, Vancouver, ISO, and other styles

46

Montastruc, Jean-Louis, Geneviève Durrieu, Agnès Sommet, Christine Damase-Michel, and Maryse Lapeyre-Mestre. "Anticholinergics, antimuscarinics or atropinics? About the words in pharmacology." British Journal of Clinical Pharmacology 69, no. 5 (2010): 561–62. http://dx.doi.org/10.1111/j.1365-2125.2010.03633.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kobayashi, Seiji, Ken Ikeda, Masako Hirano, et al. "Effects of antimuscarinics on urinary bladder and salivary gland." Japanese Journal of Pharmacology 71 (1996): 328. http://dx.doi.org/10.1016/s0021-5198(19)37550-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

MacDiarmid, S. "Better management of patients with overactive bladder with antimuscarinics?" International Journal of Clinical Practice 62, no. 1 (2007): 3. http://dx.doi.org/10.1111/j.1742-1241.2007.01627.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

MacDiarmid, Scott A. "Combination antimuscarinics and α-blockers for benign prostatic hyperplasia". Current Urology Reports 9, № 4 (2008): 265–71. http://dx.doi.org/10.1007/s11934-008-0047-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

MacDiarmid, Scott A. "Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia." Current Prostate Reports 5, no. 2 (2007): 71–77. http://dx.doi.org/10.1007/s11918-007-0010-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!